8A01312MB WHITE LIQUID COLOR YELLOW 486-33492-3 PP FR 8-6 LMS-1000

Homepage // News Center // Avient Featuring Colorants and Additives for Recycling Challenges at the 2023 Plastics Recycling Conference Avient will also be showcasing its newly launched PCR Color Prediction Service – a digital tool that supports post-consumer recycled (PCR) resin coloration.   Avient will exhibit at booth #710 in the Gaylord National Resort & Convention Center in Maryland, March 6-8, 2023.

Also announced are two new Edgetek™ PKE non-halogen flame retardant (NHFR) formulations made with polyketone, which can have a lower carbon footprint compared to polyamide 6 reinforced materials, and are pre-colored in orange for high-voltage connectors in electric vehicles. The new Edgetek PKE NHFR formulations can be laser marked and are pre-colored in orange for high-voltage applications in EVs. Other colors are also available for custom formulations. 

Informacja o realizowanej strategii podatekowej Avient Colorants Poland Sp. z o.o. za rok podatkowy 2022 Spółka Avient Colorants Poland („Spółka”) NIP 7320000991 zgodnie z art. 27c ustawy o podatku dochodowym od osób prawnych (tj. Avient Colorants Poland składa także na potrzeby transakcji wewnątrzwspólnotowych deklarację VAT-UE. Podatek od nieruchomości Właścicielem budynków i gruntów jest Avient Colorants Poland.

Informacja o realizowanej strategii podatkowej Avient Colorants Poland Sp. z o.o. za rok podatkowy 2023 Spółka Avient Colorants Poland („Spółka”) NIP 7320000991 zgodnie z art. 27c ustawy o podatku dochodowym od osób prawnych (t.j. Avient Colorants Poland składa także na potrzeby transakcji wewnątrzwspólnotowych deklarację VAT-UE. Podatek od nieruchomości Właścicielem budynków i gruntów jest Avient Colorants Poland.

Bio-based Polymer Colorants and Additives Mevopur™ Healthcare Colorants and Formulations: color concentrates and ready-to-use formulations to add color and enhance the performance of medical plastics, developed with raw materials pre-tested to ISO, USP, EP, and ICH Q3D protocols Remafin™ EP White Colorants: white concentrates pre-tested to European Pharmacopeia standards for use with polyethylene and polypropylene pharmaceutical packaging

Mevopur™ Healthcare Colorants and Formulations Polyolefin Healthcare Whites: Remafin™ EP Range of white colorants developed for use in pharmaceutical packaging

February 6, 2018 Our expertise in polymer science enables us to develop formulations with unique colors, with excellent levels of transparency or opacity, and with superior mechanical properties.” PolyOne is exhibiting at MD&M West in Anaheim, California, in booth 2101 from February 6-8, 2018.

Factors that could cause actual results to differ materially from those implied by these forward-looking statements include our ability to identify and evaluate acquisition targets and consummate acquisitions; the ability to successfully integrate acquired businesses into our operations, such as Magna Colours, retain the management teams of acquired businesses, and retain relationships with customers of acquired businesses; our ability to achieve the strategic and other objectives relating to the acquisition of Clariant's Masterbatch business, including any expected synergies; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; the current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve the anticipated financial benefit from initiatives related to acquisition and integration working capital reductions, cost reductions and employee productivity goals; information systems failures and cyberattacks; and amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions.

Factors that could cause actual results to differ materially from those implied by these forward-looking statements include disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; the current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows; our ability to achieve the strategic and other objectives relating to the acquisition of Clariant's Masterbatch business, including any expected synergies; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve the anticipated financial benefit from initiatives related to acquisition and integration working capital reductions, cost reductions and employee productivity goals; our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; information systems failures and cyberattacks; our ability to consummate and successfully integrate acquisitions; and amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions.